Table 2. Primers used for screening and subtyping of HLA-A*02 alleles.
Primera | Sequences (5′–3′) | Intron/exon | Nucleotide locationb | Ref. |
---|---|---|---|---|
For main-screening | ||||
78C-FW1c | CTCGCCCCCAGGCTCC | Intron 1, exon 2 | (120–130), 74–78 | 12 |
78C-FW2c | CCTCGTCCCCAGGCTCC | Intron 1, exon 2 | (119–130), 74–78 | |
78T-FW | CCTCGTCCCCAGGCTCT | Intron 1, exon 2 | (119–130), 74–78 | 19–22 |
A-I3-RV | GTCCCAATTGTCTCCCCTC | Intron 3 | (83–65) | 24d |
77G-FW | TCCTCGTCCCCAGGCTG | Intron 1, exon 2 | (118–130), 74–77 | |
538A-RV | GTGCTTGGTGGTCTGAGCT | Exon 3 | 556–538 | |
hB2M-FW | CCGATATTCCTCAGGTACTC | 12d | ||
hB2M-RV | ACACAACTTTCAGCAGCTTAC | 12d | ||
For sub-screening | ||||
318A-FW | GACGGGGAGACACGGAAA | Exon 2 | 301–318 | |
555A-RV | GCCGCCTCCCACTTGT | Exon 3 | 570–555 | |
149C-FW | CCCCGCTTCATCGCC | Exon 2 | 135–149 | |
440G-RV | CGGAGGAAGCGCCC | Exon 3 | 453–440 | |
412A-FW | GTTCTCACACCATCCAGATA | Exon 3 | 393–412 | |
555G-RV | GCCGCCTCCCACTTGC | Exon 3 | 570–555 | |
For sequencing or cloning | ||||
A-I1-FW | CCTCTGYGGGGAGAAGCAA | Intron 1 | (28–46) | 24d |
A-I4-RV | CAGAGAGGCTCCTGCTTTC | Intron 4 | (54–36) | |
Seq-I2-RV | TCGGACCCGGAGACTGTG | Intron 2 | (81–64) | |
Seq-I2-FW | GTTTCATTTTCAGTTTAGGCCA | Intron 2 | (148–169) | |
Seq-I3-FW | GGTGTCCTGTCCATTCTC | Intron 3 | (507–524) | |
For ambiguity resolving | ||||
A-F5-FW | GATTCCCCAACTCCGCAG | 5′-flanking region | (−198–(−181)) | |
78T-RV | GAAGAAATACCTCATGGAGTGA | Exon 2 | 99–78 | |
Seq-I1-RV | CTCATGGAGTGAGAGCCTGG | Exon 2, intron 1 | 89–74, (130–127) |
Group- or allele-specific primers are named (polymorphic position and nucleotide)-FW/RV, locus-specific primers are named (locus)-(intron/exon)-FW/RV and sequencing primers are referred to as Seq-(Intron/Exon)-FW/RV.
The exon nucleotides are numbered according to the alignment of coding DNA sequences of HLA-A alleles in the IMGT/HLA database.2 The 5′-flanking region and intron passages are shown in the brackets and numbered according to Kotsch et al.25
78C-FW1 and 78C-FW2 were synthesized separately and mixed at a 1∶1 mole ratio before use and designated as 78C-FW.
With 5′ nucleotide truncations from or additions to previously reported sequences.